In 2015, a national biobank
in rheumatology (Dansk Reuma Biobank) was established. The biobank is based at
We are investigating if it is possible by use of one single blood sample to predict which treatment is best for the individual patient (personalized medicine).
In one study based on DANBIO, we have identified several genes that may influence the efficacy of biological treatments (Krintel et al., 2012).
In patients with axial spondyloarthritis, we have demonstrated that the relation between disease activity and soluble biomarkers for inflammation, cartilage and bone turnover changes during treatment with Tumor-Necrosis-Factor-Alpha (TNFα) inhibitors (Pedersen et al., 2011).